JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Erasca Inc

Closed

1.55 -8.28

Overview

Share price change

24h

Current

Min

1.53

Max

1.66

Key metrics

By Trading Economics

Income

1.3M

-31M

Employees

103

EBITDA

-750K

-36M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+150% upside

Dividends

By Dow Jones

Next Earnings

8 Aug 2025

Market Stats

By TradingEconomics

Market Cap

31M

425M

Previous open

9.83

Previous close

1.55

Technical Score

By Trading Central

Confidence

Bearish Evidence

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 Jul 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 Jul 2025, 23:54 UTC

Acquisitions, Mergers, Takeovers

EQT To Start Tender Offer for Fujitec

29 Jul 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 Jul 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 Jul 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 Jul 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 Jul 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 Jul 2025, 22:35 UTC

Earnings

IGO Maintains Nova Life of Mine Production Guidance

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 Jul 2025, 22:34 UTC

Market Talk
Earnings

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 Jul 2025, 22:33 UTC

Earnings

IGO Had A$279.7 Million of Cash at End-June

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Underlying Free Cash A$2.4 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO FY Sales Revenue A$512.5 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO FY Nickel Production 17,173 Tons

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 Jul 2025, 22:31 UTC

Earnings

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 Jul 2025, 22:31 UTC

Earnings

IGO FY Spodumene Production 1.48 Million Tons

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Underlying Ebitda A$62 Million

29 Jul 2025, 22:22 UTC

Earnings

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

150% upside

12 Months Forecast

Average 4.25 USD  150%

High 6 USD

Low 3 USD

Based on 4 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.39 / 1.44Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Very Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.